Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with mild cognitive impairment (MCI) — a condition involving minor memory or thinking difficulties — based on specific test scores (a MoCA score below 27 and a CDR score of 0.5)
- People who have been diagnosed with Metabolic Syndrome, which means having abdominal obesity (waist measurement over 102cm for men or over 88cm for women), plus high fasting blood sugar (above 110 mg/dL), plus at least one of the following: unhealthy cholesterol or triglyceride levels, or high blood pressure (above 130/85 mmHg)
- People who are fluent in Hebrew
- People who have another person (such as a family member or carer) who is able to actively participate in the study alongside them
Who may not be able to join:
- People who have been diagnosed with diabetes of any type
- People who are currently taking medications that can affect blood sugar levels, including a type of medication called GLP-1 receptor agonists (confirm with trial site)
- People who have been diagnosed with dementia (any form) or other conditions that directly affect thinking or memory
- People with a short life expectancy or a medical condition that would make it difficult to take part in the study consistently
- People for whom insulin or Semaglutide (the medications used in this trial) are medically unsuitable
- People taking medications such as corticosteroids that may affect blood sugar levels
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tal Davidy, Sheba Medical Center
Phone: +972-35307262
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cognitive change - The effect of the combination of Semaglutide and intranasal insulin on cognitive functioning.; Neuroimaging outcome -- The effect of the combination of Semaglutide and intranasal insulin on cerebral blood flow (CBF).; Neuroimaging outcome -- The effect of the combination of Semaglutide and intranasal insulin on brain glucose intake.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.